21 June 2021

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

2021-06-21T13:44:55-07:00

*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC2021-06-21T13:44:55-07:00
21 June 2021

Ask the Experts: Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies

2021-06-21T13:19:15-07:00

*June 2021* This webinar focuses on necessary testing, common mechanisms of EGFR-dependent resistance, and possible treatment strategies. Dr. Josh Bauml

Ask the Experts: Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies2021-06-21T13:19:15-07:00
21 June 2021

The SINDAS Trial – The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC

2021-06-21T12:41:34-07:00

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to

The SINDAS Trial – The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC2021-06-21T12:41:34-07:00
20 June 2021

Osimertinib Combos Under Evaluation to Improve Outcomes, Combat Resistance in EGFR+ NSCLC

2021-06-20T16:38:03-07:00

*April 2021* Jyoti D. Patel, MD, discusses how the FDA approval of adjuvant osimertinib has impacted the treatment of patients

Osimertinib Combos Under Evaluation to Improve Outcomes, Combat Resistance in EGFR+ NSCLC2021-06-20T16:38:03-07:00
Go to Top